Caladrius Biosciences (NASDAQ: CLBS) is one of 186 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its peers? We will compare Caladrius Biosciences to related companies based on the strength of its risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Caladrius Biosciences and its peers, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Caladrius Biosciences 0 0 1 0 3.00
Caladrius Biosciences Competitors 537 2404 6597 125 2.65

Caladrius Biosciences presently has a consensus target price of $7.00, indicating a potential upside of 102.90%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 22.51%. Given Caladrius Biosciences’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Caladrius Biosciences is more favorable than its peers.

Profitability

This table compares Caladrius Biosciences and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Caladrius Biosciences -84.10% -96.80% -43.98%
Caladrius Biosciences Competitors -3,313.51% -538.79% -39.59%

Volatility and Risk

Caladrius Biosciences has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500. Comparatively, Caladrius Biosciences’ peers have a beta of 1.55, suggesting that their average share price is 55% more volatile than the S&P 500.

Earnings & Valuation

This table compares Caladrius Biosciences and its peers top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Caladrius Biosciences $35.28 million -$32.65 million 1.64
Caladrius Biosciences Competitors $217.29 million -$39.39 million -92.76

Caladrius Biosciences’ peers have higher revenue, but lower earnings than Caladrius Biosciences. Caladrius Biosciences is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

6.4% of Caladrius Biosciences shares are owned by institutional investors. Comparatively, 49.3% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 13.1% of Caladrius Biosciences shares are owned by insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Caladrius Biosciences beats its peers on 7 of the 12 factors compared.

Caladrius Biosciences Company Profile

Caladrius Biosciences, Inc. is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company is focused on commencing The Sanford Project: T-Rex Study, a Phase II prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate its Treg product candidate, CLBS03, in adolescents with recent onset T1D. The Company plans to develop its product candidate, CLBS12, in Japan, which is an autologous therapy that derives its cells from peripheral blood through apheresis.

Receive News & Stock Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related stocks with our FREE daily email newsletter.